Duchenne muscular dystrophy: diagnosis and perspective of treatment

References

[1] BonifatiDM,ErmaniM,AngeliniC.The glucocorticoid receptor N363S polymorphism and steroid response in Duchenne dystrophy.J Neurol Neurosurg Psychiatry2006;77:1177-9

[2] BiggarWD,FehlingsDL,SteeleCA.Deflazacort treatment of Duchenne muscular dystrophy.J Pediatr2001;138:45-50.

[3] GuglieriM,McDermottMP.Effect of different corticosteroid dosing regimens on clinical outcomes in boys with duchenne muscular dystrophy: a randomized clinical trial.JAMA2022;327:1456-68

[4] SmithEC,HoffmanEP.Efficacy and safety of vamorolone in Duchenne muscular dystrophy: an 18-month interim analysis of a non-randomized open-label extension study.PLoS Med2020;17:e1003222 PMCID:PMC11231869

[5] AngeliniC.Advances in imaging of brain abnormalities in neuromuscular disease.Ther Adv Neurol Disord2019;12:1756286419845567 PMCID:PMC7505441

[6] MatthewsE,KuntzerT,ManzurAY.Corticosteroids for the treatment of Duchenne muscular dystrophy.Cochrane Database Syst Rev2016;2016:CD003725 PMCID:PMC8580515

[7] McDonaldCM,AbreschRT.Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study.Lancet2018;391:451-61

[8] OkuboM,HayashiS.Exon skipping induced by nonsense/frameshift mutations in DMD gene results in Becker muscular dystrophy.Hum Genet2020;139:247-55 PMCID:PMC6981323

[9] SheikhO.Pharmacology and toxicology of eteplirsen and SRP-5051 for DMD exon 51 skipping: an update.Arch Toxicol2022;96:1-9

[10] StraubV.An update on Becker muscular dystrophy.Curr Opin Neurol2023;36:450-4 PMCID:PMC10487383